Catumaxomab

CHEMBL2108581 Phase 4 Disetujui Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A trifunctional bispecific antibody that simultaneously targets EpCAM on tumor cells and CD3 on T cells, recruiting immune effector cells to kill cancer cells. It was historically used for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. It was withdrawn from the European market for commercial reasons despite demonstrated clinical activity.

Area Terapeutik

Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A trifunctional bispecific antibody that simultaneously targets EpCAM on tumor cells and CD3 on T cells, recruiting immune effector cells to kill cancer cells. It was historically used for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. It was withdrawn from the European market for commercial reasons despite demonstrated clinical activity.

Yes, Catumaxomab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108581. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Catumaxomab di PillFYI

Data Cepat

Tautan Eksternal

ChEMBL CHEMBL2108581

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.